| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-1570 | |
| Phytochemical name or plant extracts | Salvianolic Acid B | |
| PMID | 31726654 | |
| Literature evidence | Since free radicals play a key role in the initiation and progression of tumor cells growth and enhance their metastatic potential, the current study was designed to investigate the antitumor activity of Sal-B and compare it with the antitumor activity of the traditional anticancer drug, cisplatin. | |
| IUPAC name | (2R)-2-[(E)-3-[(2S,3S)-3-[(1R)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyl]oxy-3-(3,4-dihydroxyphenyl)propanoic acid | |
| Phytochemicals’ class or type of plant extracts | Benzofuran | |
| Source of phytochemicals or plant Extracts | Salvia miltiorrhizae Binge | |
| Geographical availability | China North-Central, China South-Central, China Southeast, Vietnam | |
| Plant parts | Root | |
| Other cancers | Breast cancer | |
| Target gene or protein | Glutathione, TNF-?, MMP8, Cyclin D1, Ki67, Caspase 3, p53, COX-2 | |
| Gene or Protein evidence | Sal-B decreased plasma level of malondialdehyde as a marker of oxidative stress and increased plasma level of reduced glutathione (GSH) as a marker of antioxidant defense when compared to control ESC injected mice. Either Sal-B or cisplatin treatment decreased tumor tissue levels of tumor necrosis factor (TNF-?), matrix metalloproteinase-8 (MMP-8), and Cyclin D1 in ESC treated mice. Contrary to cisplatin treatment, Sal-B did not decrease tumor tissue Ki-67 protein in ESC injected mice. Immunohistochemical analysis revealed that Sal-B or cisplatin treatment increased the expression of the apoptotic markers caspase-3 and P53. Although Sal-B or cisplatin significantly reduced the expression of the angiogenic factor vascular endothelial growth factor (VEGF) in ESC injected mice, only Sal-B reduced expression level of COX-2 in ESC injected mice. | |
| Target pathways | NA | |
| IC50 | At 24h, 48h, and 72h: 4.5 mg/mL, 4.9 mg/mL, 4.6 mg/mL against MCF-7 | |
| Potency | Our data suggest that Sal-B exhibits antitumor features against breast cancer cells possibly via enhancing apoptosis and reducing oxidative stress, inflammation, and angiogenesis. | |
| Cell line/ mice model | MCF-7, ESC treated mice | |
| Additional information | NA | |
| PubChem ID | 6451084 | |
| Additional PMIDs | NA | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:456707-1 | |
| Safety | NA |